Analogues of N-hydroxycinnamoylphenalkylamides as inhibitors of human melanocyte-tyrosinase
Amides obtained by coupling caffeic acid, ferulic acid, p-hydroxycinnamoic acid, and analogues with substituted phenylalkylamines were evaluated as inhibitors of the human melanocyte-tyrosinase. The most active compounds induce a complete enzyme-inactivation at 100 μM. At the latter concentration, k...
Gespeichert in:
Veröffentlicht in: | Bioorganic & medicinal chemistry letters 2006-04, Vol.16 (8), p.2252-2255 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Amides obtained by coupling caffeic acid, ferulic acid,
p-hydroxycinnamoic acid, and analogues with substituted phenylalkylamines were evaluated as inhibitors of the human melanocyte-tyrosinase. The most active compounds induce a complete enzyme-inactivation at 100
μM. At the latter concentration, kojic acid, used as a reference, was inactive.
Melanin play a major role in human skin protection and their biosynthesis is vital. Due to their color, they contribute to the skin pigmentation. Tyrosinase is a key enzyme involved in the first stage of melanin synthesis, catalyzing the transformation of tyrosine to
l-dopaquinone. The aim of the present study was to study molecules able to inhibit melanin synthesis through inhibition of tyrosinase and their potential use in treating pigmentation-related disorders. We targeted amides obtained from coupling
p-hydroxycinnamic acid derivatives with phenylalkylamines. The biological activity was evaluated on human melanocytes by an assay which measures tyrosine-catalyzed
l-Dopa oxidation. The most active amides were:
trans-
N-caffeoyltyramine,
N-dihydrocaffeoyltyramine, and
trans-
N-dihydro-
p-hydroxycinnamoyltyramine which induce complete inhibition at 0.1
mM. At the latter concentration, kojic acid, which was used as the reference inhibitor, was inactive. |
---|---|
ISSN: | 0960-894X 1464-3405 |
DOI: | 10.1016/j.bmcl.2006.01.022 |